Prelude Therapeutics annual net debt
2019
2021
2022
2023
2024
2025
Prelude Therapeutics Net Debt Growth & History (PRLD)
Prelude Therapeutics's net debt was −$17.5M for fiscal 2025.
View full Prelude Therapeutics company overviewPrelude Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$17.5M | −$23.0M | — |
| 2024 | 2024-12-31 | $5.6M | $14.0M | — |
| 2023 | 2023-12-31 | −$8.4M | $20.4M | — |
| 2022 | 2022-12-31 | −$28.8M | $1.3M | — |
| 2021 | 2021-12-31 | −$30.1M | — | — |
| 2019 | 2019-12-31 | −$18.6M | — | — |
Prelude Therapeutics quarterly net debt
Q4.19
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$8.7M | −$844,000 | — |
| Q1 2026 | 2026-03-31 | −$4.0M | $18.3M | — |
| Q4 2025 | 2025-12-31 | −$17.5M | −$23.0M | — |
| Q3 2025 | 2025-09-30 | −$29.7M | −$36.7M | — |
| Q2 2025 | 2025-06-30 | −$7.8M | $1.8M | — |
| Q1 2025 | 2025-03-31 | −$22.3M | −$15.3M | — |
| Q4 2024 | 2024-12-31 | $5.6M | $14.0M | — |
| Q3 2024 | 2024-09-30 | $7.0M | $22.4M | — |
| Q2 2024 | 2024-06-30 | −$9.6M | $15.9M | — |
| Q1 2024 | 2024-03-31 | −$7.1M | $9.7M | — |
| Q4 2023 | 2023-12-31 | −$8.4M | $20.4M | — |
| Q3 2023 | 2023-09-30 | −$15.4M | $35.2M | — |
| Q2 2023 | 2023-06-30 | −$25.5M | $23.4M | — |
| Q1 2023 | 2023-03-31 | −$16.8M | $32.6M | — |
| Q4 2022 | 2022-12-31 | −$28.8M | $1.3M | — |
| Q3 2022 | 2022-09-30 | −$50.6M | $8.6M | — |
| Q2 2022 | 2022-06-30 | −$48.9M | $292.3M | — |
| Q1 2022 | 2022-03-31 | −$49.4M | $311.4M | — |
| Q4 2021 | 2021-12-31 | −$30.1M | — | — |
| Q3 2021 | 2021-09-30 | −$59.3M | — | — |
| Q2 2021 | 2021-06-30 | −$341.2M | — | — |
| Q1 2021 | 2021-03-31 | −$360.7M | — | — |
| Q4 2019 | 2019-12-31 | −$18.6M | — | — |
Prelude Therapeutics net debt trends
Between the periods ended 2019-12-31 and 2025-12-31, Prelude Therapeutics's net debt increased from −$18.6M to −$17.5M, a change of $1.2M. The latest reported quarter, Q2 2026, shows −$8.7M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prelude Therapeutics source filings ↗Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...